Human Breast Adenocarcinoma Cell MDA-MB Transfection Kit
| Kit size Volume | Quantity | ||
|---|---|---|---|
| 0.5 ml(Cat-179390) | Inquiry | Add to cart | |
| 1.5 ml(Cat-179491) | Inquiry | Add to cart | |
| 1.5 ml CRISPR(Cat-217092) | Inquiry | Add to cart | |
| 8.0 ml(Cat-706093) | Inquiry | Add to cart |
Description
Product Information
Modes of administration
Reagent exhibits at least 80% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Description
Breast cancer, a scourge of humanity that has claimed innumerable lives of women worldwide, remains a preeminent cause of cancer-related fatalities in the fairer sex. To gain deeper insights into the diverse and variegated forms of this debilitating disease, researchers have resorted to utilizing breast cancer cell lines. One such cell line, the MDA-MB-453, was procured from a human breast adenocarcinoma sample back in 1976, and has since been subjected to extensive scrutiny to unravel the intricacies of this formidable adversary.
The MDA-MB-453 cells have certain idiosyncratic features that render them an invaluable asset for research purposes. These cells exhibit a heightened expression of fibroblast growth factor (FGF) receptors, a characteristic that has been shown to play a critical role in driving the progression of specific forms of breast cancer. By probing how the MDA-MB-453 cells react to diverse external stimuli, researchers have garnered precious insights into the fundamental mechanisms that underpin the emergence and propagation of breast cancer.
MDA-MB-453 cells are ideally suited for unraveling the role of androgen receptors in breast cancer cell proliferation and gene expression. Additionally, MDA-MB-453 cells are particularly responsive to specific drugs, which bestows upon them an invaluable tool for scrutinizing the efficacy of novel chemotherapy agents. The versatility of these cells, when it comes to testing their reaction to different drugs, provides an excellent platform for developing precisely-targeted therapies that can be fine-tuned to tackle the unique features of diverse forms of breast cancer.
To optimize the efficacy of transfection in MDA-MB-453 cells, CD BioSciences provides pre-optimized high-efficiency transfection reagent kits, specifically designed to facilitate efficient transfection.
